Announcements Trials
Browse Landscape

Phase

Phase 1/2 30Phase 1 29Phase 2 25Phase 3 9Phase NA 6Phase 4 4Phase 2/3 3Phase EARLY_PHASE1 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 86Glioblastoma 82Pancreatic Neoplasms 76Glioma 66Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 55Colorectal Neoplasms 55Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 51Recurrence 47Squamous Cell Carcinoma of Head and Neck 46Ovarian Neoplasms 45Lymphoma 40Lymphoma, Non-Hodgkin 37Sarcoma 36Lymphoma, B-Cell 36Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 34Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

toripalimab 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Epstein-Barr Virus Infections × Clear all
NCT06224049 2024-03-12

GI-hNeoT-01

BGI, China

Phase EARLY_PHASE1 Recruiting
6 enrolled
Lymphoid

Lymphoma, T-Cell, Epstein-Barr Virus Infections

NCT04690036 2021-06-29

PD-1 Antibody for Reactive EBV After BMT

Beijing Friendship Hospital

Phase EARLY_PHASE1 Unknown
20 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡